GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.



Similar documents
General Rules SEER Summary Stage Objectives. What is Staging? 5/8/2014

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Early Prostate Cancer: Questions and Answers. Key Points

Directly Coded Summary Stage Is Back

Prostate Cancer In-Depth

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

Newly Diagnosed Prostate Cancer: Understanding Your Risk

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

A918: Prostate: adenocarcinoma

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

Us TOO University Presents: Understanding Diagnostic Testing

Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

DIAGNOSIS OF PROSTATE CANCER

An Introduction to PROSTATE CANCER

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.

Thyroid and Adrenal Gland

PATIENT GUIDE. Localized Prostate Cancer

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

Treatment Part Two 1 FLORIDA CANCER DATA SYSTEM Treatment - Part Two

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

Prostate Cancer Screening. Dr. J. McCracken, Urologist

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives.

Kidney Cancer OVERVIEW

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

1. What is the prostate-specific antigen (PSA) test?

THYROID CANCER. I. Introduction

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

PCA3 DETECTION TEST FOR PROSTATE CANCER DO YOU KNOW YOUR RISK OF HAVING CANCER?

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

7. Prostate cancer in PSA relapse

PSA Screening for Prostate Cancer Information for Care Providers

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

一 本 共 識 依 下 列 參 考 資 料 修 改 版 本 : 1. NCCN Clinical Practice Guidelines in Oncology- Prostate cancer V

Prostate Cancer. What is cancer?

The PSA Test for Prostate Cancer Screening:

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

A912: Kidney, Renal cell carcinoma

Does my patient need more therapy after prostate cancer surgery?

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

Prostate Cancer Management Clinical Guidelines

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for

Report series: General cancer information

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization N = 50

Thymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.

7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Melanoma of Skin. Overview. This webinar is sponsored by

CONTENTS: WHAT S IN THIS BOOKLET

Prostate Specific Antigen (PSA) Blood Test

The PSA Controversy: Defining It, Discussing It, and Coping With It

Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.

Prostate Cancer Action Plan: Choosing the treatment that s right for you

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

Prostate Cancer. Treatments as unique as you are

A Woman s Guide to Prostate Cancer Treatment

After Diagnosis: Prostate Cancer. Understanding Your Treatment Options

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

The Diagnosis of Cancer in the Pathology Laboratory

Prostate Cancer & Its Treatment

Neoplasms of the LUNG and PLEURA

Frozen Section Diagnosis

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival

Science Highlights. To PSA or not to PSA: That is the Question.

OBJECTIVES By the end of this segment, the community participant will be able to:

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Advanced Prostate Cancer Treatments

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures:

In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? Telephone

The Ontario Cancer Registry moves to the 21 st Century

Avastin: Glossary of key terms

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

LCD for Prostate Specific Antigen (PSA)

Treating Localized Prostate Cancer A Review of the Research for Adults

Diagnosis of Recurrent Prostate Tumor at Multiparametric Prostate MRI: Pearls and Pitfalls

Advances in Differentiated Thyroid Cancer

Lung Cancer: Diagnosis, Staging and Treatment

Transcription:

GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate cases diagnosed on or after January 1, 1995 to ensure that EOD Extension codes 33 and 34 are used instead of 31. All treatment modalities such as surgery, radiation, and hormones, can be administered for any stage. If the only information you have is a report showing cancer in the prostate and there is no mention of extraprostatic disease, assign code 30, localized, NOS, rather than unknown. Codes 10-30 are all localized disease and are not hierarchical (the numerically higher code is not the preferred choice). Choose the code that best describes the individual case. Code clinically inapparent tumors as 10, or 13-15; clinically apparent tumors as 20 or 23-24; and unknown if inapparent or apparent to 30. SEER has provided a list of terms in the Extent of Disease Manual, Third Edition, page 135, to assist in distinguishing apparent from inapparent tumors. DIAGNOSIS DATE If the medical record states that a patient was newly or recently diagnosed and the date of diagnosis is not stated, code diagnosis date to the date of admission Exception: For history-only cases, do not use the date of admission; instead, determine the date of diagnosis. CLINICAL EOD Code what you do know even if the workup is not complete. If the only information you have is a pathology report from a prostate needle biopsy, code the clinical extension 30, localized NOS, rather than unknown. Adhere to the EOD terminology in the SEER Coding Manual when coding EOD/Stage. If a term is a term of involvement, code the extension. Do not use terms of non-involvement to code stage. Example 1: Needle biopsy of the prostate shows adenocarcinoma. Bone scan shows possible metastasis. Possible is a term of non-involvement. The case is coded to localized rather than distant or unknown (EOD clinical extension is coded 11-30, depending upon the procedure and available information.) Exception: If the patient is treated for extension or metastasis, use that information to code the EOD extension even if the terminology is one of non-involvement. Example 2: The bone scan shows possible metastasis in the lumbar spine. The physician orders radiation to the lumbar spine. Code the extension as 85 (metastatic) even though the term possible is one of non-involvement. Statewide Distribution June 27, 2002 1 California Cancer Registry

Only clinical information is used to assign clinical EOD, do not use information from the prostatectomy to code the clinical EOD. Example 3: Patient has a hard nodule extending bilaterally to the apex on PE. Clinical extension is coded to 34. Patient has a prostatectomy that shows cancer confined to left lobe and an adenoma in right apex. Pathologic extension is coded to 20, but clinical extension remains 34. PATHOLOGIC EOD Pathologic EOD uses all clinical information as well as the information from pathology reports, including the pathology from a needle biopsy. Example 4: On PE, a hard nodule extends bilaterally to the apex. Needle biopsy of right apex was positive. Patient then had a prostatectomy that showed cancer in left lobe only. Combine the information from the needle biopsy and the prostatectomy and code the pathologic EOD to 34 (T2). Clinically Inapparent Tumor Codes 10-15 Note: These codes were created for special studies and need to be as uncontaminated as possible. Use these codes only if you are sure the cancer was not clinically apparent. Example 5: A physician statement of T1c prostate cancer would be a statement that the cancer was clinically inapparent. Please see the list of terms SEER has provided (EOD Manual, page 135) to assist in distinguishing clinically apparent from inapparent tumors. If you are not sure whether or not a case was clinically apparent, use code 30 (apparent or inapparent). GUIDELINES FOR SPECIFIC CODES Code 10 Use this code when the percentage of involved tissue is unknown. This code should be used when the only information you have is Stage A, NOS. Codes 13-14 These codes are based on the percent of resected tissue involved at TURP. There must be some statement indicating the percent of tissue involved. If the weight in grams is given for both the total amount of tissue resected and the tissue containing tumor, calculate the percentage by dividing the grams of tumor tissue by the grams of tissue resected. If weight is not given, use the number of involved chips and the total number of chips to calculate the percentage. Example 6: If the pathology states there are 3/40 chips involved, Divide 3 by 40 = 7.5%. Code to 14 (incidental finding in more than 5% of tissue resected). Assume that all chips and positive foci are of equal size. If the pathology report states solitary focus of carcinoma without mentioning the total amount of tissue resected, code the case to 13. Note: For coding purposes, the terminology tissue examined is synonymous with tissue resected. Statewide Distribution June 27, 2002 2 California Cancer Registry

When to use code 15 vs codes 30-34 (How to determine if there is sufficient information to code to 15) Code 15 is for cases diagnosed on prostate needle biopsy. Use code 15 when the following criteria are met: There is documentation that the PSA was elevated or there is no documentation about the PSA. AND There is documentation that the physical exam was negative AND If a TRUS was done, there is documentation that the findings were negative. Use codes 30-34: The prostatic apex is involved OR When there is no documentation saying that physical exam was benign OR When there was a TRUS but there is no documentation that the examination was negative. Inapparent or Apparent Tumor (Please see guidelines for determining whether a case should be coded to 15 or 30.) EOD clinical extension should rarely be coded to 31. If you know only the apex is involved, it should be coded to 33 (arising in prostatic apex). If there is involvement of the apex and any other area of prostate, and there is no mention that it arose in the apex, it should be coded to 34 (extending into prostatic apex). Code 31 should only be used when you have a statement that the apex is involved, but you have no detailed documentation (such as a path report or a clinical description of the path findings) to verify whether it fits into code 33 or 34. When involvement of the apex is mentioned clinically and there are multiple positive prostate biopsies without mention of which areas of the prostate were biopsied, code to 34. Example 7: Coding to 33: PE: Admit for prostatectomy. Adenocarcinoma, right apex and possibly left mid prostate. The pathology from the biopsy is not available. Example 8: Coding to 34: PE: Admit for prostatectomy. Adenocarcinoma of prostate, present on the right side and crosses the midline to the left apex. The pathology from the biopsy is not available. PE: Admit for treatment consult. Medical record documents that biopsies of the right base, mid gland and apex were positive for adenocarcinoma. The pathology from the biopsy is not available. PE: US single hypoechoic lesion, left apex. Pathology report: Multiple biopsies on left, adenocarcinoma. No mention of which areas were biopsied. Statewide Distribution June 27, 2002 3 California Cancer Registry

Code 90 EOD clinical extension will rarely be coded to 90. Cases coded to 90 will probably be limited to: History only cases Death certificate only cases PSA elevated above 50 and absence of other information for coding EOD Incidental finding on prostatectomy or autopsy. Code 90 would be used here even if there were a prostate exam, because prior to an incidental finding the physician has no suspicion that there is a malignancy (there has been no needle biopsy or TURP). Example 9: Cases to be coded to 90: Patient has cystoprostatectomy for bladder cancer and prostate exam prior to surgery was benign. Patient has suprapubic prostatectomy because of urinary retention and BPH. Prostate ca is not suspected. EOD PATHOLOGICAL EXTENSION Question asked of SEER: At prostatectomy, seminal vesicles and margins are involved. Should extension be code 45 or 48? Answer: Use code 48. EOD LYMPH NODES Clinical Information Only Code lymph nodes as not involved (0) when the only information available is clinical (from scans and physical examination) and any of the following terms are used to describe the lymph nodes: Lymphadenopathy Enlarged nodes No lymphadenopathy No enlarged nodes Exam of lymph nodes within normal limits (WNL) Exam of lymph nodes negative Note: This list is intended as an example, it does not list all negative terms. No Clinical or Pathologic Information When there is no clinical or pathological information on LN s, use code 0 (none) when clinical and /or pathological extension is coded from 10-34. If clinical and/or pathological extension is coded from 40-90, use code 9 (unknown). Use the following guidelines for coding PSA: PSA = 10.0 or above, code = 1 (positive/elevated) PSA = 4.0 and below, code = 2 (negative/normal) PSA = 4.1-9.9; code = 3 (borderline) PSA Note: Physician statement has priority over recorded values. If the physician states that the PSA is elevated or that there has been a significant rise in PSA, code to 1 (elevated). Generally PSA level will only be used to assist in coding EOD if it is very elevated (above 50). In the absence of other EOD information, if the PSA level is above 50 do not code the case to localized. Statewide Distribution June 27, 2002 4 California Cancer Registry

Example 10: H&P: Admit for multiple medical problems. PSA on admission was 258. DX: Probable prostate cancer. Patient s family wishes no further work-up. EOD clinical extension should be coded to 90. Statewide Distribution June 27, 2002 5 California Cancer Registry